Sanctura Muscarinic Receptor Antagonist Resists Transport (SMART-II) Trial

Completed · Phase 4 · Has a placebo group

Conditions studied: Overactive Bladder

In brief

This study will evaluate the cerebrospinal fluid levels of trospium chloride (Sanctura XR®) and oxybutynin immediate release (Oxybutynin IR) on memory performance in patients with overactive bladder and age associated memory impairment.

Key facts

Study ID

NCT01178827

Run by

Allergan

People needed

20

Starts

2010-08-01

Expected to finish

2011-03-01

Last updated by the study team

2016-02-26

Who can join

Age: 60 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patient presents symptoms of overactive bladder
• Patient has age associated memory impairment
• No acute or unstable medical conditions

You may not qualify if…

• History of alcohol or substance abuse within 1 year prior to study
• Has donated in excess of 500mL of blood or plasma in the 30 days prior to study
• Has known bleeding disorder (hemophilia)
• Previous abdominal bypass surgery for obesity

Where it is running

• Study site — Salt Lake City, Utah, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.